BCG bladder cancer thrapeutic - Chengdu CoenBiotech
Latest Information Update: 09 May 2024
At a glance
- Originator Chengdu CoenBiotech
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Bladder cancer
Most Recent Events
- 11 Nov 2022 Phase-I clinical trials in Bladder cancer (Adjuvant therapy) in China (Intravesicular) (NCT06350838)